BCM
LLY icon

BlueCrest Capital Management’s Eli Lilly LLY Stock Holding History

BlueCrest Capital Management’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,300
Closed -$15M – 180
2024
Q1 		$15M Sell
19,300
-8,100
-30% -$5.76M 0.74% 23
2023
Q4 		$16M Buy
27,400
+9,500
+53% +$5.55M 0.61% 33
2023
Q3 		$9.61M Buy
+17,900
New +$9.22M 0.42% 44

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlueCrest Capital Management's LLY Position: Q1 2026 in Review

BlueCrest Capital Management sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 19,635 shares — an estimated $21.1M sold.

BlueCrest Capital Management first reported a position in LLY in Q4 2017 and held it in 12 quarters. The position peaked at $38.5M in Q3 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • BlueCrest Capital Management reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • BlueCrest Capital Management sold 19,635 Eli Lilly shares in Q1 2026, an estimated $21.1M.
  • BlueCrest Capital Management first reported a position in Eli Lilly in Q4 2017 and held it in 12 quarters.
  • BlueCrest Capital Management's Eli Lilly position peaked at $38.5M in Q3 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on BlueCrest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.